OTTAWA, March 7 /CNW/ - Liponex Inc. (TSX:LPX), a biopharmaceutical
company specializing in developing advanced products related to High Density
Lipoprotein (HDL), often called "good cholesterol," today announced results of
the Phase I/II Clinical Trial of its lead product, CRD5. CRD5 is being
developed for the treatment of dyslipidemia and heart disease. Results showed,
to date, that CRD5 was safe and that the drug formulation was stable
throughout the trial. However, the mean increase in HDL levels from the
baseline, in both the 1 and 3 gram dosages was less than 5% and not
statistically significant. The patient to patient variation was high and while
some patients showed a strong increase in HDL, other patients had negative
response. The Company will continue to assess the data from this trial over
the next several weeks.
